BioMin Clinical papers – Sensitivity

Clinical Papers : Reducing Sensitivity / Dentine Hypersensitivity

Evaluation of Bioactive Glass Treatment for Dentin Hypersensitivity: A Systematic Review

Compared with the control groups, fluoro calcium phosphosilicate (FCPS) may be the most effective long-term treatment option. In terms of DH symptom reduction, the FCPS group performed better than the CSPS group.

Comparative Evaluation of Desensitizing Dentifrices containing BioMin®, Novamin® and Fluoride on Dentinal Tubule Occlusion before and after a Citric Acid Challenge

The % of occluded tubles (cause of sensitivity) with BioMin® containing dentifrice (toothpaste) was significantly higher than NovaMin® and a control i.e., fluoride containing dentifrice.  Biomin ® and Novamin® containing dentifrices showed significant citric acid resistance compared to the fluoride containing dentifrice although the BioMin® containing dentifrice significantly showed better resistance to a citric acid challenge than the NovaMin® containing dentifrice.

In Australia NovaMin® is registered to GlaxoSmithKlein.  

Evaluation of Bioactive Glass Treatment for Dentin Hypersensitivity: A Systematic Review

The calcium sodium phosphosilicate group (CSPS) was not significantly different from the positive control groups. Compared with the control  groups, fluoro calcium phosphosilicate (FCPS) may be the most effective long-term treatment option. In terms of DH symptom reduction, the FCPS group performed better than the CSPS group.

Comparative Evaluation of Desensitizing Efficacy of Dentifrice Containing 5% Fluoro Calcium Phosphosilicate Versus 5% Calcium Sodium Phosphosilicate: A Randomized Controlled Clinical Trial

The fluoro calcium phosphosilicate group (BioMin® F)  showed a higher degree of effectiveness in reducing DH (Dentine Hypersensitivity), followed by calcium sodium phosphosilicate (NovaMin® ) then standard fluoride dentifrices (toothpastes).

Clinical comparison of 5% fluoro calcium phosphosilicate (BioMin® F) versus 5% calcium sodium phosphosilicate (NovaMin®) in the treatment of dentinal hypersensitivity.
It was found that though significant reduction in hypersensitivity was observed for all three groups over time, flouro calcium phosphosilicate (BioMin® F) was most effective in reducing the VAS (pain) score, followed by calcium sodium phosphosilicate (NovaMin®) and fluoride  It was concluded that fluoro calcium phosphosilicate is a promising agent for clinical management of dentinal hypersensitivity.
A Randomised Clinical Trial on the Efficacy of 5% Fluoro calcium Phosphosilicate-Containing Novel Bioactive Glass Toothpaste

The toothpaste containing 5% fluoro calcium phosphosilicate (BioMin F) was reported to be more efficacious than the other two toothpastes (B, 8% arginine and calcium carbonate, fluoride placebo)  in managing DH. This novel development opens up a unique opportunity in the prevention and management of DH and may also be beneficial in preventing acid erosion of the tooth surface and in the maintenance of oral hygiene by reducing the effects of plaque accumulation and gingival inflammation.

Comparative assessment of effectiveness of Biomin, NovaMin, herbal, and potassium nitrate desensitizing agents in the treatment of hypersensitive teeth: A clinical study

The Biomin® group showed significantly better results compared with either NovaMin®, herbal, and potassium nitrate toothpastes in the treatment of dental hypersensitivity symptoms.

Comparative efficacy of BioMin-F, Colgate Sensitive Pro-relief and Sensodyne Rapid Action in relieving dentin hypersensitivity: a randomized controlled trial

Based on the synthesis of study results, we can conclude that Pro-Argin™ in Colgate Sensitive Pro-relief™ and 8% strontium acetate in Sensodyne Rapid Action™ both are effective for pain relief in one minute after application in DH with better immediate treatment response of Pro-Argin™ than strontium acetate. While FCPS in BioMin® F can be the best possible treatment option for long-term management of DH in the form of OTC dentifrices.